Imatinib Drug Market Size, Share, Growth and Industry Report 2024-2031

Imatinib Drug Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Global Imatinib Drug Market is segmented&nbsp;By Application (Chronic Eosinophilic Leukemia, Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), Others),&nbsp;By Drug Formulation (Capsules, Tablets),&nbsp;By End Use (Hospital Pharmacies, Ambulatory Surgical Centers, Clinics, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,&nbsp;2024-2031</h2>&nbsp;<h3>Imatinib Drug Market Overview</h3><blockquote>The Global Imatinib Drug Market is estimated to reach at a high CAGR during the forecast period (2024-2031).&nbsp;Several factors are propelling the growth of the market such as the increase in demand for target drug therapy and patient expiry of imatinib drugs.&nbsp;North America is holding a major market share in the global imatinib drug market due to increasing incidences of cancer and growing healthcare concerns.&nbsp;Competitive rivalry intensifies Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd and others operating in the market.</blockquote>Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases. Imatinib is designed to target abnormal proteins that promote the growth and survival of cancer cells and that are unique to these cells.<h3>Imatinib Drug Market Dynamics</h3>The global imatinib drug market growth is driven by the increasing prevalence of cancer, increase in demand for target drug therapy, and patient expiry of imatinib drugs.Increase in demand of target drug therapy and patient expiry of imatinib drugFor instance, according to National Cancer Institute in 2017, the number of new cases for <a target="_blank" rel="noopener noreferrer" href="https://datamintelligence.com/research-report/leukemia-market">Leukemia</a> is 62,130, and the number of deaths was 24,500 which shows the increasing prevalence of cancer patients in the future and propels the imatinib drug market. In addition, Food and Drug Administration (FDA) approves enasidenib a target drug therapy for patients who has Acute myeloid leukemia (specifically genetic mutation IDH2). Moreover, the Imatinib drug helps treat patients with cancer by blocking the growth of eosinophils. This drug has been attributed to its higher efficacy in treating&nbsp;Chronic Eosinophilic Leukemia, Hyper-Eosinophilic Syndrome, Gastrointestinal Stromal Tumors (GIST), and many more. These factors are driving the growth of the market in the forecast period.The increasing prevalence of cancer will drive the market growth in the forecast periodThe increase in awareness of cancer by government and private organizations is anticipated to boost the market growth. According to the National Cancer Institute, in June 2017, it was estimated that there will be around 62,130 and 24,500 people with new cases and death due to leukemia, respectively, in the U.S. &nbsp;In addition, R&amp;D activities related to imatinib are anticipated to present new opportunities during the forecast period.The high cost of imatinib is likely to hinder the market growthHowever, the high cost of imatinib, adverse effects, presence of substitutes, such as Sprycel, Tarceva, and Tasigna, and stringent government regulations may hinder the market growth.<h3>COVID-19 Impact On&nbsp;Imatinib Drug Market</h3>Imatinib is a tyrosine kinase inhibitor that has been approved for the treatment of many hematologic and solid neoplasm. Imatinib demonstrates in vitro activity against SARS-CoV viruses. Imatinib inhibits COVID 19 with micromolar EC50s nutrient absorption. It is also reported that imatinib may also be important for the replication of two members of the Coronaviridae family, SARS-CoV, and MERS-CoV. In vivo studies performed in the mouse model of vaccinia virus infection showed that imatinib was effective in blocking the dissemination of the virus.The investigators hypothesize that the addition of imatinib to the best conventional care (BCC) improves the outcome of hospitalized adult patients with COVID-19. This hypothesis is based on 1) intralysosomal entrapment of imatinib will increase endosomal pH and effectively decrease, because of the critical role of mechanical ventilation in the care of patients with ARDS, imatinib will have a significant clinical impact for patients with severe COVID-19 infection in Intensive Care Unit (ICU). This factor will increase the sale of imatinib drugs in the forecast period.<h3>Imatinib Drug Market Segmentation Analysis</h3>The chronic Eosinophilic Leukemia &nbsp;segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)Chronic eosinophilic leukemia will show healthy growth in the future attributed to the increasing prevalence of cancers. <a target="_blank" rel="noopener noreferrer" href="https://datamintelligence.com/research-report/chronic-eosinophilic-leukemia-market">Chronic Eosinophilic Leukemia</a> (CEL) is a disorder in which eosinophil count is greater than 1500 µl in peripheral blood also called hyper-eosinophilia. It is a rare myeloproliferative neoplasm, overproduction of eosinophils in the bone marrow. This imatinib drug helps in treating the disorder by stopping the tyrosine kinase enzyme which blocks the abnormal eosinophils. Imatinib drug is more beneficial in patients who have leukemia from a genetic mutation. Moreover, the Imatinib drug also helps in improving blood counts and symptoms very fast which makes this drug highly adopted by the targeted patient pool and promotes the revenue growth of the imatinib drug market. &nbsp;Gastrointestinal Stromal Tumors (GIST) is the second-largest share in the market due to the type of tumor that arises in the gastrointestinal tract (stomach and small intestine). Imatinib has been the first-line therapy for GIST. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells. The rising research activities have resulted in the development of innovative and advanced therapeutics, thus supporting the growth of the segment.The imatinib capsules are expected to dominate the imatinib drug market during the forecast period &nbsp;&nbsp;The imatinib capsules have the highest large in the market. Imatinib capsule is a medicine containing an active substance called imatinib. This medicine works by inhibiting the growth of abnormal cells in the diseases. The dosage is based on medical condition, response to treatment, and other medications. Imatinib capsules have 50 and 100 mg, film-coated tablets 100 and 400 mg product. The recommended dose of imatinib is 600 mg/day for adult patients with hematological experts in the management of this disease should supervise the therapy throughout all phases of care. Based on the existing data, imatinib is effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase.For instance, according to Cancer Research UK, new cases for pancreatic cancer accounted for almost 10, 257 in the United Kingdom, for 2015-2017. This factor is driving the growth of the market.<h3>Imatinib Drug Market Geographical Share</h3>North America region holds the largest market share global imatinib drug marketNorth America is holding a major market share in the global imatinib drug market due to increasing incidences of cancer and growing healthcare concerns. As per the National Cancer Institute, in 2018 an estimate of 1.7 million new cases of cancer was diagnosed wherein these drugs were used and thus promoting the growth of the imatinib drug market. Moreover, R&amp;D expenditure in healthcare (oncology) is also anticipated to propel the growth of the imatinib drug market in the region. Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.<h3>Imatinib Drug Companies and Competitive Landscape</h3>The Imatinib Drug market is moderately competitive with the presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Inc, and <a target="_blank" rel="noopener noreferrer" href="https://www1.apotex.com/products/us/detail.asp?m=68115">Apotex </a>Inc, Sanofi S.A., Actavis Generics, and others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the imatinib drug market globally. &nbsp;&nbsp;<h3>Imatinib Drug Market Key Companies to Watch</h3>Dr. Reddy's LaboratoriesOverview: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, providing medicines through its three businesses segment - Pharmaceutical Services &amp; Active Ingredients, Global Generics, and Proprietary Products. The 5000-member team network connects with more than three lakh doctors regularly to ensure that quality medicines we make are available for patients across the length and breadth of the country. The company has progressively transitioned from being a maker of molecules to a provider of medicines. Dr. Reddy operates in markets across the globe. Company major markets include USA, India, Russia &amp; CIS countries, and Europe.Product Portfolio: The Company’s portfolio has over 200 products covering the whole spectrum of disease areas spanning gastroenterology, oncology, pain management, cardiovascular, dermatology, urology, nephrology, rheumatology, and diabetes. Seven brands are listed in the Top-300 of the Indian Pharma Market.Key Development: In July 2018, Dr. Reddy’s Laboratories launched imatinib Mesylate tablets, a generic version of Novartis' blockbuster anti-cancer drug Gleevec, in the US market the drug is used in treating chronic myeloid leukemia. The company has received US Food and Drug Administration (USFDA) approval to manufacture and market the product.<h3>Trending Reports:</h3><a target="_blank" rel="noopener noreferrer" href="https://datamintelligence.com/research-report/metabolic-disorders-therapeutics-market">Metabolic Disorders Therapeutics Market</a><a target="_blank" rel="noopener noreferrer" href="https://datamintelligence.com/research-report/insulinoma-treatment-market">Insulinoma Treatment Market</a>&nbsp;

<ol><li>Methodology and Scope<ol><li>Research Methodology</li><li>Research Objective and Scope of the Report</li></ol></li><li>Market Definition and Overview</li><li>Executive Summary<ol><li>Market Snippet by &nbsp;Application</li><li>Market snippet by Drug Formulation</li><li>Market snippet by End Use</li><li>Market Snippet by Region</li></ol></li><li>Market Dynamics<ol><li>Market Impacting Factors<ol><li>Drivers<ol><li>Increase in demand of target drug therapy</li><li>Prevalence of cancer</li></ol></li><li>Restraints:<ol><li>Presence of substitute drug</li></ol></li><li>Opportunity</li><li>Impact Analysis</li></ol></li></ol></li><li>Industry Analysis<ol><li>Porter's Five Forces Analysis</li><li>Supply Chain Analysis</li><li>Pricing Analysis</li><li>Regulatory Analysis</li><li>Reimbursement Analysis</li><li>Unmet Needs</li></ol></li><li>COVID-19 Analysis<ol><li>Analysis of Covid-19 on the Market<ol><li>Before COVID-19 Market Scenario</li><li>Present COVID-19 Market Scenario</li><li>After COVID-19 or Future Scenario</li></ol></li><li>Pricing Dynamics Amid Covid-19</li><li>Demand-Supply Spectrum</li><li>Government Initiatives Related to the Market During Pandemic</li><li>Manufacturers Strategic Initiatives</li><li>Conclusion </li></ol></li><li>By Application<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment</li><li>Market Attractiveness Index, By Application Segment</li></ol></li><li>Chronic Eosinophilic Leukemia *<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li></ol></li><li>Philadelphia Positive Chronic Myeloid Leukemia</li><li> Hyper-Eosinophilic Syndrome (HES)</li><li> Myelodysplastic Syndrome (MDS)</li><li> Myeloproliferative Diseases (MPD)</li><li> Gastrointestinal Stromal Tumors (GIST)</li><li>Others</li></ol></li><li>By Drug Formulation<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Attractiveness Index, By Drug Formulation</li></ol></li><li>Capsules *<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li></ol></li><li>Tablets</li></ol></li><li>By End Use<ol><li>Introduction<ol><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use Segment</li><li>Market Attractiveness Index, By End Use Segment</li></ol></li><li>Hospital Pharmacies &nbsp;*<ol><li>Introduction</li><li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li></ol></li><li>Ambulatory Surgical Centers</li><li> Clinics</li><li> Other</li></ol></li><li>By Region<ol><li>Introduction<ol><li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li><li>Market Attractiveness Index, By Region</li></ol></li><li>North America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>U.S.</li><li>Canada</li><li>Mexico</li></ol></li></ol></li><li>Europe<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Germany</li><li>U.K.</li><li>France</li><li>Italy</li><li>Spain</li><li>Rest of Europe</li></ol></li></ol></li><li>South America<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>Brazil</li><li>Argentina</li><li>Rest of South America</li></ol></li></ol></li><li>Asia Pacific<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country<ol><li>China</li><li>India</li><li>Japan</li><li>Australia</li><li>Rest of Asia Pacific</li></ol></li></ol></li><li>Middle East and Africa<ol><li>Introduction</li><li>Key Region-Specific Dynamics</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation</li><li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use</li></ol></li></ol></li><li>Competitive Landscape<ol><li>Key Developments and Strategies</li><li>Company Share Analysis</li><li>Product Benchmarking</li><li>List of key companies to watch</li><li>List of the company with disruptive technology</li><li>List of start-up companies</li></ol></li><li>Company Profiles<ol><li>Sun Pharmaceutical Industries Ltd. *<ol><li>Company Overview</li><li>Product Portfolio and Description</li><li>Key Highlights</li><li>Financial Overview</li></ol></li><li>Novartis AG</li><li> Dr. Reddy’s Laboratories Ltd</li><li> Teva Pharmaceutical Industries Ltd.</li><li>Mylan N.V.</li><li> Cipla Inc</li><li> Apotex Inc,</li><li>Sanofi S.A.</li><li> Actavis Generics</li><li>Glenmark Pharmaceuticals Ltd.(*LIST NOT EXHAUSTIVE)</li></ol></li><li>DataM Intelligence<ol><li>Appendix</li><li>About Us and Services</li><li>Contact Us</li></ol></li></ol>

List of TablesTable 01 Global Imatinib Drug Market Value, By Application, 2023,2027 &amp; 2031 ($ Million)Table 02 Global Imatinib Drug Market Value, By &nbsp;Drug Formulation, 2023,2027 &amp; 2031 ($ Million)"Table 03 Global Imatinib Drug Market Value, By End Use, 2023,2027 &amp; 2031 ($ Million)Table 04 Global Imatinib Drug Market Value, By Region, 2023,2027 &amp; 2031 ($ Million)Table 05 Global Imatinib Drug Market Value, By Application, 2023,2027 &amp; 2031 ($ Million)Table 06 Global Imatinib Drug Market Value, By Application, 2022-2031 ($ Million)Table 07 Global Imatinib Drug Market Value, By Drug Formulation, 2023,2027 &amp; 2031 ($ Million)"Table 08 Global Imatinib Drug&nbsp; Market Value, By &nbsp;Drug Formulation, 2022-2031 ($ Million)"Table 09 Global Imatinib Drug&nbsp; Market Value, By End Use, 2023,2027 &amp; 2031 ($ Million)Table 10 Global Imatinib Drug&nbsp; Market Value, By End Use, 2022-2031 ($ Million)Table 11 Global Imatinib Drug&nbsp; Market Value, By Region, 2023,2027 &amp; 2031 ($ Million)Table 12 Global Imatinib Drug&nbsp; Market Value, By Region, 2022-2031 ($ Million)Table 13 North America Imatinib Drug&nbsp; Market Value, By Application, 2022-2031 ($ Million)Table 14 North America Imatinib Drug&nbsp; Market Value, By Drug Formulation, 2022-2031 ($ Million)"Table 15 North America Imatinib Drug &nbsp;Market Value, By End Use, 2022-2031 ($ Million)Table 16 North America Imatinib Drug&nbsp; Market Value, By Country, 2022-2031 ($ Million)Table 17 South America Imatinib Drug&nbsp; Market Value, By Application, 2022-2031 ($ Million)Table 18 South America Imatinib Drug&nbsp; Market Value, By Drug Formulation, 2022-2031 ($ Million)"Table 19 South America Imatinib Drug&nbsp; Market Value, By End Use, 2022-2031 ($ Million)Table 20 South America Imatinib Drug&nbsp; Market Value, By Country, 2022-2031 ($ Million)Table 21 Europe Imatinib Drug&nbsp; Market Value, By Application, 2022-2031 ($ Million)Table 22 Europe Imatinib Drug&nbsp; Market Value, By &nbsp;Drug Formulation, 2022-2031 ($ Million)"Table 22 Europe Imatinib Drug&nbsp; Market Value, By End Use, 2022-2031 ($ Million)Table 23 Europe Imatinib Drug&nbsp; Market Value, By Country, 2022-2031 ($ Million)Table 24 Asia-Pacific Imatinib Drug&nbsp; Market Value, By Application, 2022-2031 ($ Million)Table 25 Asia-Pacific Imatinib Drug&nbsp; Market Value, By &nbsp;Drug Formulation, 2022-2031 ($ Million)"Table 26 Asia-Pacific Imatinib Drug&nbsp; Market Value, By End Use, 2022-2031 ($ Million)Table 27 Asia-Pacific Imatinib Drug&nbsp; Market Value, By Country, 2022-2031 ($ Million)Table 28 Middle East &amp; Africa Imatinib Drug&nbsp; Market Value, By Application, 2022-2031 ($ Million)Table 29 Middle East &amp; Africa Imatinib Drug&nbsp; Market Value, By&nbsp;Drug Formulation, 2022-2031 ($ Million)"Table 30 Middle East &amp; Africa Imatinib Drug&nbsp; Market Value, By End Use, 2022-2031 ($ Million)Table 31 Sun Pharmaceutical Industries Ltd.: Overview"Table 31 Sun Pharmaceutical Industries Ltd.: Product Portfolio"Table 32 Sun Pharmaceutical Industries Ltd.: Key Developments"Table 33 Novartis AG: OverviewTable 34 Novartis AG: Product PortfolioTable 35 Novartis AG: Key DevelopmentsTable 36 Dr. Reddy’s Laboratories Ltd: OverviewTable 37 Dr. Reddy’s Laboratories Ltd: Product PortfolioTable 38 Dr. Reddy’s Laboratories Ltd: Key DevelopmentsTable 40 &nbsp;Teva Pharmaceutical Industries Ltd.: OverviewTable 41 &nbsp;Teva Pharmaceutical Industries Ltd.: Product PortfolioTable 42 &nbsp;Teva Pharmaceutical Industries Ltd.: Key DevelopmentsTable 43 Mylan N.V.: OverviewTable 44 Mylan N.V.: Product PortfolioTable 45 Mylan N.V.: Key DevelopmentsTable 46 Cipla Inc: OverviewTable 47 Cipla Inc: Product PortfolioTable 48 Cipla Inc: Key DevelopmentsTable 49 Apotex Inc: OverviewTable 50 Apotex Inc: Product PortfolioTable 51 Apotex Inc: Key DevelopmentsTable 52 Sanofi S.A.: OverviewTable 53 Sanofi S.A.: Product PortfolioTable 54 Sanofi S.A.: Key DevelopmentsTable 55 Actavis Generics: OverviewTable 56 Actavis Generics: Product PortfolioTable 57 Actavis Generics: Key DevelopmentsTable 58 Glenmark Pharmaceuticals Ltd.: OverviewTable 59 Glenmark Pharmaceuticals Ltd.: Product PortfolioTable 60 Glenmark Pharmaceuticals Ltd.: Key Developments&nbsp;List of FiguresFigure 01 Global Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 02 Global Imatinib Drug&nbsp; Market Share, By &nbsp;Drug Formulation, 2022 &amp; 2031 (%)"Figure 03 Global Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 04 Global Imatinib Drug&nbsp; Market Share, By Region, 2022 &amp; 2031 (%)Figure 05 Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 06 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By Application, 2022-2031 (%)Figure 07 Chronic Eosinophilic Leukemia: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 08 Philadelphia Positive Chronic Myeloid Leukemia: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 09 Hyper-Eosinophilic Syndrome (HES): Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 10 Myelodysplastic Syndrome (MDS): Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 11 &nbsp;Myeloproliferative Diseases (MPD): Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 12 Gastrointestinal Stromal Tumors (GIST): Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 13 Others: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 14 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By&nbsp;Drug Formulation, 2022-2031 (%)"Figure 15 Capsules: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 16 Tablets: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 17 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By End Use, 2022-2031 (%)Figure 18 &nbsp;Hospital Pharmacies: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 19 Ambulatory Surgical Centers: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 20 Clinics: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 21 other: Global Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 22 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By 0, 2022-2031 (%)Figure 23 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By 0, 2022-2031 (%)Figure 24 Global Imatinib Drug&nbsp; Market Y-o-Y Growth, By Region, 2022-2031 (%)Figure 25 North America Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 26 North America Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 27 North America Imatinib Drug&nbsp; Market Share, By Drug Formulation, 2022 &amp; 2031 (%)"Figure 28 North America Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 29 North America Imatinib Drug&nbsp; Market Share, By 0, 2022 &amp; 2031 (%)Figure 30 North America Imatinib Drug&nbsp; Market Share, By 0, 2022 &amp; 2031 (%)Figure 31 North America Imatinib Drug&nbsp; Market Share, By Country, 2022 &amp; 2031 (%)Figure 32 South America Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 33 South America Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 34 South America Imatinib Drug&nbsp; Market Share, By Drug Formulation, 2022 &amp; 2031 (%)"Figure 35 South America Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 36 South America Imatinib Drug&nbsp; Market Share, By 0, 2022 &amp; 2031 (%)Figure 37 South America Imatinib Drug&nbsp; Market Share, By 0, 2022 &amp; 2031 (%)Figure 38 South America Imatinib Drug&nbsp; Market Share, By Country, 2022 &amp; 2031 (%)Figure 39 Europe Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 40 Europe Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 41 Europe Imatinib Drug&nbsp; Market Share, By Drug Formulation, 2022 &amp; 2031 (%)"Figure 42 Europe Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 43 Europe Imatinib Drug&nbsp; Market Share, By Country, 2022 &amp; 2031 (%)Figure 44 Asia-Pacific Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 45 Asia-Pacific Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 46 Asia-Pacific Imatinib Drug&nbsp; Market Share, By &nbsp;Drug Formulation, 2022 &amp; 2031 (%)"Figure 47 Asia-Pacific Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 48 Asia-Pacific Imatinib Drug&nbsp; Market Share, By Country, 2022 &amp; 2031 (%)Figure 49 Middle East &amp; Africa Imatinib Drug&nbsp; Market Value, 2022-2031 ($ Million)Figure 50 Middle East &amp; Africa Imatinib Drug&nbsp; Market Share, By Application, 2022 &amp; 2031 (%)Figure 51 Middle East &amp; Africa Imatinib Drug&nbsp; Market Share, By &nbsp;Drug Formulation, 2022 &amp; 2031 (%)"Figure 52 Middle East &amp; Africa Imatinib Drug&nbsp; Market Share, By End Use, 2022 &amp; 2031 (%)Figure 53 Sun Pharmaceutical Industries Ltd.: Financials"Figure 54 Novartis AG: FinancialsFigure 55 Dr. Reddy’s Laboratories Ltd: FinancialsFigure 56 &nbsp;Teva Pharmaceutical Industries Ltd.: FinancialsFigure 57 Mylan N.V.: FinancialsFigure 58 Cipla Inc: FinancialsFigure 59 Apotex Inc: FinancialsFigure 60 Sanofi S.A.: FinancialsFigure 61 Actavis Generics: FinancialsFigure 62 Glenmark Pharmaceuticals Ltd.: Financials